Research Sample bioBank
Can’t find what you’re looking for? Contact us.
Or, need help ordering? 805.528.4341
Get Weekly Research Sample Updates in your Inbox:
Hepatitis C (HCV) Clinical Research Samples
Discovery Life Sciences provides the highest quality Hepatitis C (HCV) Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Hepatitis C (HCV) Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
Advanced Data View:
Showing 410 of 410 total samples
Buy | Product ID | Sample | Origin | Matrix | Vial (ml) | Quantity | Price | Age | Gender | Ethnicity | Storage Temp | Sample Date | Test 1 | Test Data 1 | Sample Detail 1 | Test 2 | Test Data 2 | Sample Detail 2 | Test 3 | Test Data 3 | Sample Detail 3 | Product Details | Price | Buy | Additional Information 1 | Additional Data 1 | Additional Detail 1 | Additional Information 2 | Additional Data 2 | Additional Detail 2 | Additional Information 3 | Additional Data 3 | Additional Information 4 | Additional Data 4 | Additional Information 5 | Additional Data 5 | Additional Detail 5 | Additional Information 6 | Additional Data 6 | Additional Detail 6 | Additional Information 7 | Additional Data 7 | Additional Detail 7 | ICD10 codes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DLS12-0191 | Hepatitis C (HCV) | Italy | Serum | 1.00 | 2.00 | $65.00 | 75 Y | F | U/A | <-70°C | 09-Aug-12 | Abbott Realtime PCR | 6,140,000 IU/mL | HCV | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Dental Care Surgery | Symptoms | Fatigue | Additional Testing | ALT: 60 AST: 87 Bilirubin: 0.8 Serum Creatinine: 0.84 mg/dL Liver Disease Diagnosis: 1995 Chronic Hepatitis | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||||
| DLS12-0377 | Hepatitis C (HCV) | Italy | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 57 Y | M | U/A | <-70°C | 19-Jul-12 | Abbott Realtime PCR | 653 IU/mL | HCV | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Surgery | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 20; AST: 43; ALP: 300; LDH: 349; Bilirubin: 1.59; Serum Creatinine: 1.02 mg/dL; Liver Disease Diagnosis: 2005; Hepatic Cirrhosis | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||||
| DLS12-0385 | Hepatitis C (HCV) | Italy | K2 EDTA Plasma | 1.00 | 2.00 | $65.00 | 68 Y | F | U/A | <-70°C | 24-Jul-12 | Abbott Realtime PCR | HCV/RNA Positive | HCV | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Surgery | Symptoms | Fatigue | Additional Testing | ALT: 26; AST: 33; ALP: 48; LDH: 386; Bilirubin: 0.83; Serum Creatinine: 0.82 mg/dL; Liver Disease Diagnosis: 1983; Hepatocellular Carcinoma 2012 | Hepatitis Serology Result | anti HCV+ (Abbott) | |||||||||||||||||
| DLS12-0410 | Hepatitis C (HCV) | Italy | Plasma | 1.00 | 5.00 | $85.00 | 73 Y | M | White | <-70°C | 11-Sep-12 | Abbott Realtime PCR | 21,196 IU/mL | Siemens TruGene HCV | 1b | $85.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Dental Care | Symptoms | Fatigue | Additional Testing | ALT: 46; AST: 33; ALP: 44; LDH: 237; Bilirubin: 1.24; Serum Creatinine: 0.85 mg/dL; Chronic Hepatitis | Hepatitis Serology Result | anti-HCV+; anti-HBe+; HBeAg- (Abbott) | ||||||||||||||||
| DLS13-03202 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 47 Y | M | U/A | <-70°C | 09-Dec-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(2+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03203 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 7.00 | $30.00 | 39 Y | M | U/A | <-70°C | 17-Oct-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03204 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 42 Y | M | U/A | <-70°C | 20-Feb-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03206 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 39 Y | F | U/A | <-70°C | 18-Mar-05 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(3+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03207 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 35 Y | F | U/A | <-70°C | 06-Mar-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(1+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03210 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 37 Y | M | U/A | <-70°C | 15-Mar-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(3+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03211 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 52 Y | F | U/A | <-70°C | 19-Apr-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03212 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 27 Y | F | U/A | <-70°C | 04-Mar-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03214 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 49 Y | F | U/A | <-70°C | 03-Oct-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03215 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 35 Y | F | U/A | <-70°C | 03-May-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03217 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 45 Y | M | U/A | <-70°C | 14-May-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(3+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03218 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 40 Y | M | U/A | <-70°C | 21-May-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(3+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03219 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 53 Y | M | U/A | < -70C | 01-Feb-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03220 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 6.00 | $30.00 | 42 Y | F | U/A | < -70C | 26-Sep-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(+/-) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03222 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 40 Y | F | U/A | < -70C | 08-Sep-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(3+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03223 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 54 Y | M | U/A | < -70C | 18-Nov-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03224 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 31 Y | F | U/A | < -70C | 15-Oct-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(2+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03226 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 37 Y | M | U/A | < -70C | 04-Mar-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(1+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03227 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 37 Y | M | U/A | < -70C | 14-Jun-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03228 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 25 Y | M | U/A | < -70C | 06-Apr-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03229 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 43 Y | M | U/A | < -70C | 13-May-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03230 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 35 Y | M | U/A | < -70C | 20-Sep-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(-) c33(4+) c22(4+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03231 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 34 Y | F | U/A | < -70C | 04-Oct-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(+/-) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03232 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 40 Y | F | U/A | < -70C | 06-Jul-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(1+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03233 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 38 Y | F | U/A | < -70C | 20-Aug-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03234 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 52 Y | F | U/A | < -70C | 30-Aug-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03235 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 35 Y | M | U/A | < -70C | 20-Jul-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03236 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 31 Y | M | U/A | < -70C | 23-Apr-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03240 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 41 Y | M | U/A | < -70C | 07-Jan-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03241 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 60 Y | F | U/A | < -70C | 05-May-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(2+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03242 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 38 Y | F | U/A | < -70C | 10-Jan-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(2+) c33(4+) c22(4+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03243 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 55 Y | F | U/A | < -70C | 23-Sep-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03245 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 41 Y | F | U/A | < -70C | 12-May-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(3+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03246 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 40 Y | F | U/A | < -70C | 11-Mar-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(+/-) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03247 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 37 Y | M | U/A | < -70C | 24-Apr-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(3+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03248 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 34 Y | M | U/A | < -70C | 12-Feb-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Negative | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(2+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03249 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 34 Y | M | U/A | < -70C | 12-Jul-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03250 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 59 Y | M | U/A | < -70C | 11-Mar-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03251 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 59 Y | F | U/A | < -70C | 11-Mar-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(2+) c22(4+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03252 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 41 Y | M | U/A | < -70C | 12-Apr-09 | Chiron HCV RIBA | Positive | Abbott PRISM | 7.75 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03255 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 51 Y | F | U/A | < -70C | 12-May-10 | Chiron HCV RIBA | Positive | Abbott PRISM | 5.85 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(3+) c33(3+) c22(4+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03256 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 49 Y | M | U/A | < -70C | 05-Jan-08 | Chiron HCV RIBA | Positive | Abbott PRISM | 10.54 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03257 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 62 Y | M | U/A | < -70C | 02-Jul-10 | Chiron HCV RIBA | Positive | Abbott PRISM | 6.05 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03258 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 50 Y | M | U/A | < -70C | 27-Feb-08 | Chiron HCV RIBA | Positive | Abbott PRISM | 9.69 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03259 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 19 Y | F | U/A | < -70C | 29-Jan-10 | Chiron HCV RIBA | Positive | Abbott PRISM | 6.66 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03260 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 24 Y | M | U/A | < -70C | 10-Jan-08 | Chiron HCV RIBA | Positive | Abbott PRISM | 8.37 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(2+) c33(4+) c22(2+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03261 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 43 Y | M | U/A | < -70C | 06-Feb-08 | Chiron HCV RIBA | Positive | Abbott PRISM | 8.08 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03262 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 57 Y | M | U/A | < -70C | 25-Jun-10 | Chiron HCV RIBA | Positive | Abbott PRISM | 6.35 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03263 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 50 Y | F | U/A | < -70C | 28-Jan-08 | Chiron HCV RIBA | Positive | Abbott PRISM | 5.47 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(+/-) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03264 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 6.00 | $30.00 | 33 Y | M | U/A | < -70C | 22-Jul-10 | Chiron HCV RIBA | Positive | Abbott PRISM | 5.63 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(3+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03265 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 2.00 | $30.00 | 44 Y | M | U/A | < -70C | 27-Jun-10 | Chiron HCV RIBA | Positive | Abbott PRISM | 6.67 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(-) c33(2+) c22(3+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03266 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 27 Y | M | U/A | < -70C | 13-Nov-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(-) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03267 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 37 Y | M | U/A | < -70C | 29-May-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(3+) c33(2+) c22(4+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03270 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 35 Y | M | U/A | < -70C | 21-Nov-07 | Chiron HCV RIBA | Positive | Abbott PRISM | 9.63 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03271 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 49 Y | M | U/A | < -70C | 17-Mar-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03272 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 48 Y | F | U/A | < -70C | 11-Apr-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03273 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 54 Y | M | U/A | < -70C | 24-Jan-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Negative | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03274 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 30 Y | M | U/A | < -70C | 21-Dec-06 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03275 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 29 Y | M | U/A | < -70C | 09-Dec-06 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03276 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 51 Y | F | U/A | < -70C | 17-Nov-06 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(2+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03277 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 62 Y | F | U/A | < -70C | 26-Apr-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03279 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 35 Y | M | U/A | < -70C | 08-Feb-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03282 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 40 Y | F | U/A | < -70C | 13-Dec-06 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(2+) c33(4+) c22(4+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03283 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 61 Y | M | U/A | < -70C | 03-Feb-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(3+) c33(4+) c22(4+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03284 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 43 Y | M | U/A | < -70C | 31-May-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03285 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 39 Y | M | U/A | < -70C | 25-Nov-06 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03287 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 44 Y | M | U/A | < -70C | 02-Dec-06 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03288 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 54 Y | M | U/A | < -70C | 23-Oct-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03290 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 38 Y | M | U/A | < -70C | 30-Nov-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03291 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 28 Y | F | U/A | < -70C | 20-Nov-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(-) c33(4+) c22(4+) NS5(2+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03292 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 45 Y | M | U/A | < -70C | 16-Aug-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(2+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03293 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 42 Y | F | U/A | < -70C | 27-May-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03294 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 18 Y | F | U/A | < -70C | 18-Apr-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(+/-) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03295 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 43 Y | F | U/A | < -70C | 03-Sep-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03296 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 53 Y | F | U/A | < -70C | 03-Jan-05 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03297 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 24 Y | M | U/A | < -70C | 18-Sep-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Negative | $30.00 | HCV RIBA Pattern | c100(2+) c33(+/-) c22(3+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03299 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 59 Y | F | U/A | < -70C | 05-Apr-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(2+) c33(4+) c22(4+) NS5(2+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03300 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 41 Y | M | U/A | < -70C | 21-Mar-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03301 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 40 Y | M | U/A | < -70C | 04-Oct-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03302 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 32 Y | M | U/A | < -70C | 04-Apr-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03303 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 42 Y | F | U/A | < -70C | 28-Nov-07 | Chiron HCV RIBA | Positive | Abbott PRISM | 5.95 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03304 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 45 Y | M | U/A | < -70C | 17-Oct-04 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03305 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 38 Y | F | U/A | < -70C | 26-Mar-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(2+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03306 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 6.00 | $30.00 | 59 Y | F | U/A | < -70C | 29-Jan-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(3+) c33(2+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03307 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 38 Y | M | U/A | < -70C | 02-Feb-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03308 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 41 Y | M | U/A | < -70C | 26-May-07 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03309 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 28 Y | M | U/A | < -70C | 20-Nov-10 | Chiron HCV RIBA | Positive | Abbott PRISM | 7.48 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03310 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 49 Y | F | U/A | < -70C | 30-Nov-11 | Chiron HCV RIBA | Positive | Abbott PRISM | 1.73 S/Co | HCV RNA | Negative | $30.00 | HCV RIBA Pattern | c100(2+) c33(2+) c22(2+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03311 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 38 Y | M | U/A | < -70C | 13-Feb-12 | Chiron HCV RIBA | Positive | Abbott PRISM | 6.9 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03313 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 59 Y | F | U/A | < -70C | 22-Dec-11 | Chiron HCV RIBA | Positive | Abbott PRISM | 1.12 S/Co | HCV RNA | Negative | $30.00 | HCV RIBA Pattern | c100(3+) c33(2+) c22(-) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03314 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 41 Y | M | U/A | < -70C | 10-Dec-11 | Chiron HCV RIBA | Positive | Abbott PRISM | 8.53 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03315 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 39 Y | F | U/A | < -70C | 02-Apr-12 | Chiron HCV RIBA | Positive | Abbott PRISM | 3.69 S/Co | HCV RNA | Negative | $30.00 | HCV RIBA Pattern | c100(2+) c33(3+) c22(1+) NS5(-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03316 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 38 Y | M | U/A | < -70C | 13-Nov-10 | Chiron HCV RIBA | Positive | Abbott PRISM | 8.15 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(2+) c33(4+) c22(4+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03317 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 44 Y | M | U/A | < -70C | 04-Oct-11 | Chiron HCV RIBA | Positive | Abbott PRISM | 7.57 S/Co | HCV RNA | Negative | $30.00 | HCV RIBA Pattern | c100(+/-) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03318 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 5.00 | $30.00 | 25 Y | M | U/A | < -70C | 14-Jan-11 | Chiron HCV RIBA | Positive | Abbott PRISM | 5.4 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(2+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03319 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 47 Y | M | U/A | < -70C | 13-Sep-11 | Chiron HCV RIBA | Positive | Abbott PRISM | 2 S/Co | HCV RNA | Negative | $30.00 | HCV RIBA Pattern | c100(2+) c33(2+) c22(3+) NS5(4+) | hSOD Results | Negative | ||||||||||||||||||||||
| DLS13-03320 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 6.00 | $30.00 | 57 Y | F | U/A | < -70C | 09-Oct-03 | Chiron HCV RIBA | Positive | Abbott PRISM | Positive | $30.00 | HCV RIBA Pattern | c100(2+) c33(1+) c22(4+) NS5(+/-) | hSOD Results | Negative | ||||||||||||||||||||||||
| DLS13-03321 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 29 Y | F | < -70C | 20-Nov-10 | Chiron HCV RIBA | Positive | Abbott PRISM | 6.09 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(-) | hSOD Results | Negative | |||||||||||||||||||||||
| DLS13-03322 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 3.00 | $30.00 | 33 Y | M | < -70C | 20-Nov-10 | Chiron HCV RIBA | Positive | Abbott PRISM | 8.35 S/Co | HCV RNA | Positive | $30.00 | HCV RIBA Pattern | c100(4+) c33(4+) c22(4+) NS5(4+) | hSOD Results | Negative | |||||||||||||||||||||||
| DLS13-03323 | Hepatitis C (HCV) | Spain | Citrated Plasma | 1.00 | 4.00 | $30.00 | 30 Y | F | < -70C | 05-Aug-11 | Chiron HCV RIBA | Positive | Abbott PRISM | 2.41 S/Co | HCV RNA | Negative | $30.00 | HCV RIBA Pattern | c100(4+) c33(+/-) c22(4+) NS5(+/-) | hSOD Results | Negative | |||||||||||||||||||||||
| DLS13-05039 | Hepatitis C (HCV) | Vietnam | K2 EDTA Plasma | 1.00 | 12.00 | $65.00 | 33 Y | M | Asian | < -70C | 11-Jun-13 | Roche cobas | 137,000 IU/mL | HCV | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue | Additional Testing | ALT: 33 U/L; AST: 23 U/L; Bilirubin: 11.5 umol/L; Serum Creatinine: 90 umol/L | Hepatitis Serology | HBsAg- (ECLIA Cobas 6000) | |||||||||||||||||
| DLS13-05043 | Hepatitis C (HCV) | Vietnam | Plasma | 1.00 | 3.00 | $85.00 | 24 Y | M | Asian | < -70C | 06-Jun-13 | Roche cobas | 71,800 IU/mL (HCV RNA); 195,000 (HBV RNA) | Real-Time PCR | 1 | $85.00 | 3-series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice; Itching | Additional Testing | ALT: 178; AST: 138; Bilirubin: 57.9 umol/L; Serum Creatinine: 69 umol/L; Hepatitis C & B | Hepatitis Serology Result | HBsAg+; Anti HCV+ (ECLIA Cobas 6000) | Co-Infections | HBV+ | ||||||||||||||
| DLS13-05065 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 11.00 | $65.00 | 35 Y | M | Asian | < -70C | 24-Jul-13 | Roche cobas | 1,180,000 IU/mL | HCV | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue; Abdominal pain; Jaundice | Additional Testing | ALT: 153 U/L; AST: 163 U/L; Bilirubin: 17 umol/L; Serum Creatinine: 95 umol/L | Co-Infections | HIV+ | 2004 | ||||||||||||||||
| DLS13-09600 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 34 Y | M | Asian | < -70C | 06-Dec-13 | Roche cobas | 70,000,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 115 U/L; AST: 66 U/L; Serum Creatinine: 81 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2013 | ||||||||||||
| DLS13-09603 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 8.00 | $65.00 | 32 Y | M | Asian | < -70C | 21-Nov-13 | Roche cobas | 19,700,000 copies/mL | HCV | $65.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg Lamivudine 150 mg Nevirapine 200 mg | Acquired Infection Category | Unknown | Symptoms | No symptoms | Additional Testing | ALT: 25 U/L; AST: 29 U/L; Bilirubin: 7.2 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2011 | |||||||||||||
| DLS13-09646 | Hepatitis C (HCV) | Vietnam | Plasma | 1.00 | 15.00 | $95.00 | 30 Y | M | Asian | < -70C | 26-Dec-13 | Roche cobas | 7,150,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission | Symptoms | Asymptomatic | Additional Testing | ALT: 93 U/L; AST: 77 U/L; Serum Creatinine: 72 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2011 | ||||||||||||
| DLS13-11764 | Hepatitis C (HCV) | Vietnam | Plasma | 1.00 | 12.00 | $95.00 | 35 Y | M | Asian | < -70C | 23-Dec-13 | Roche cobas | 2,360,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 46 U/L; AST: 48 U/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2012 | ||||||||||||
| DLS13-11831 | Hepatitis C (HCV) | Italy | Plasma | 1.00 | 1.00 | $85.00 | 58 Y | M | White | < -70C | 27-Nov-13 | Roche cobas | 8,820 IU/mL (HBV); 207,000 IU/mL (HCV) | PCR Sequencing; Siemens TruGene HCV | D (HBV); 1b (HCV) | $85.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Sexual transmission | Symptoms | Fatigue | Additional Testing | ALT: 81; AST: 37; LDH: 383; Bilirubin: 0.6; Serum Creatinine: 0.7 mg/dL; Grade 1 Stage 2; Chronic Active Hepatitis due to HBV & HCV | Hepatitis Serology Result | HBsAg+; HDV Ab-; HBsAb-; HCV Ab+ (CMIA) | ||||||||||||||||
| DLS13-15718 | Hepatitis C (HCV) | Vietnam | Plasma | 1.00 | 11.00 | $95.00 | 39 Y | M | Asian | < -70C | 26-Dec-13 | Roche cobas | 7,150,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Lopinavir / Ritonavir 200 mg / 50 mg | Acquired Infection Category | Sexual Transmission | Symptoms | No symptoms | Additional Testing | ALT: 82 U/L; AST: 86 U/L; Serum Creatinine: 90 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2010 | ||||||||||||
| DLS13-15725 | Hepatitis C (HCV) | Vietnam | Plasma | 1.00 | 12.00 | $95.00 | 37 Y | F | Asian | < -70C | 24-Dec-13 | Roche cobas | 15,500,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 52 U/L; AST: 44 U/L; Serum Creatinine: 91 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2010 | ||||||||||||
| DLS14-05326 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 40 Y | M | Asian | < -70C | 02-Jun-14 | Roche cobas | 285,000 copies/mL | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 36; AST: 46; Serum Creatinine: 83 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2010 | ||||||||||||||
| DLS14-05331 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 21.00 | $95.00 | 39 Y | M | Asian | < -70C | 13-Mar-14 | Roche cobas | 173,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 85 U/L; AST: 257 U/L | Hepatitis Serology | Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2013 | |||||||||||||
| DLS14-05335 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 8.00 | $95.00 | 36 Y | M | Asian | < -70C | 17-Jun-14 | Roche cobas | 15,800,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 26; AST: 26; Serum Creatinine: 87 umol/L | Hepatitis Serology | HBsAg+; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2012 | ||||||||||||
| DLS14-05337 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 11.00 | $95.00 | 43 Y | M | Asian | < -70C | 28-May-14 | Roche cobas | 7,120,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 150 mg; Aluvia 200/50 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 83; AST: 73; Bilirubin: 903 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2005 | ||||||||||||
| DLS14-05343 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 11.00 | $65.00 | 31 Y | M | Asian | < -70C | 19-Jun-14 | Roche cobas | 4,800,000 copies/mL | HCV | $65.00 | 3-series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | Decreased appetite | Additional Testing | ALT: 177; AST: 115; Serum Creatinine: 67 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2005 | |||||||||||||
| DLS14-05345 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 10.00 | $95.00 | 40 Y | M | Asian | < -70C | 14-Mar-14 | Roche cobas | 9,000,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg Lamivudine 150 mg Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 102; AST: 130 | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2010 | ||||||||||||
| DLS14-05353 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 8.00 | $65.00 | 54 Y | M | Asian | < -70C | 16-May-14 | Roche cobas | 68,200 copies/mL | HCV | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Abdominal pain; Sleep disturbances; Nausea | Additional Testing | ALT: 539; AST: 414; ALP: 141; Bilirubin: 218 umol/L; Serum Creatinine: 0.64 mg/dL | |||||||||||||||||||
| DLS14-05356 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 32 Y | M | Asian | < -70C | 28-May-14 | Roche cobas | 300,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission; IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 50; AST: 46; Serum Creatinine: 77 umol/L | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2007 | ||||||||||||
| DLS14-05392 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 12.00 | $65.00 | 47 Y | F | Asian | < -70C | 09-May-14 | Roche cobas | 4,660,000 IU/mL | HCV | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice; Sleep disturbances; Depression | Additional Testing | ALT: 19; AST: 18; Bilirubin: 7.3 umol/L; Serum Creatinine: 0.6 mg/dL | |||||||||||||||||||
| DLS14-05393 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 8.00 | $65.00 | 36 Y | M | Asian | < -70C | 08-May-14 | Roche cobas | 3,550,000 copies/mL | HCV | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Zidovudine 300 mg Lamivudine 150 mg Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission | Symptoms | No symptoms | Additional Testing | ALT: 108; AST: 61 | Hepatitis Serology | HBsAg-; Anti HCV+ (Elisa) | Co-Infections | HIV+ | 2012 | |||||||||||||
| DLS14-05354 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 9.00 | $95.00 | 32 Y | M | Asian | < -70C | 15-Jul-14 | Roche cobas | 18,800,000 copies/mL | Real-Time PCR | 1 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | Sexual Transmission | Symptoms | No symptoms | Additional Testing | ALT: 178; AST: 121; Serum Creatinine: 77umol/L | 1-Jul-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 25-Aug-2010 | Co-Infections | HIV+ | 16-Aug-10 | ||||||||||
| DLS14-05358 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 12.00 | $95.00 | 54 Y | M | Asian | < -70C | 16-Sep-14 | Roche cobas | 3,700,000 IU/mL | 28-Aug-14 | Real-Time PCR | 1 | 13-Oct-14 | $95.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain | Additional Testing | ALT: 28; AST: 63; Bilirubin: 17 umol/L; Serum Creatinine: 1.14 mg/dL | 12-Sep-14 | Hepatitis Serology Result | Co-Infections | TB+ | 2013 | |||||||||||
| DLS14-05360 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 15.00 | $65.00 | 66 Y | F | Asian | < -70C | 19-Mar-14 | Roche cobas | 950 IU/mL | 10-Mar-14 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Abdominal pain; Joint pain; Sleep disturbances | Additional Testing | ALT: 17; AST: 11; Bilirubin: 27 umol/L | 11-Mar-14 | Hepatitis Serology Result | |||||||||||||||||
| DLS14-05386 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 8.00 | $65.00 | 57 Y | M | Asian | < -70C | 21-Aug-14 | Roche cobas | 11,600,000 IU/mL | 7-May-14 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Abdominal pain; Jaundice | Additional Testing | ALT: 646; AST: 977; Serum Creatinine: 1.02 mg/dL | 5-Aug-14 | Hepatitis Serology Result | Anti HCV + (Elisa) | 5-Aug-2014 | |||||||||||||||
| DLS14-05405 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 10.00 | $65.00 | 66 Y | M | Asian | < -70C | 23-Jul-14 | Roche cobas | 16,800 IU/mL | 9-Jul-14 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Abdominal pain; Jaundice | Additional Testing | ALT: 117; AST: 141; Bilirubin: 72.4 umol/L; Serum Creatinine: 0.8 mg/dL | 1-Jul-14 | Hepatitis Serology Result | Anti HCV + Elisa | 2-Jul-2014 | |||||||||||||||
| DLS14-08005 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 12.00 | $65.00 | 39 Y | M | Asian | < -70C | 06-Nov-14 | Roche cobas | 3,570,000 IU/mL | 1-Nov-14 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Jaundice; Flu-like symptoms | Additional Testing | ALT: 267 U/L; AST: 615 U/L; Bilirubin: 207 umol/L; Serum Creatinine: 0.8 mg/dL | 29-Oct-14 | Hepatitis Serology Result | Anti HCV + (Cobas) | 24-Oct-2014 | |||||||||||||||
| DLS14-07990 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 12.00 | $65.00 | 36 Y | M | Asian | < -70C | 09-Jan-15 | Roche cobas | 1,710,000 IU/mL | 6-Jan-14 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | None | Hepatitis Serology Result | None | ||||||||||||||||
| DLS14-07996 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 16.00 | $65.00 | 36 Y | F | Asian | < -70C | 30-Jan-15 | Roche cobas | 26,700 copies/mL | HCV | $65.00 | 3-series HepB Vaccine | Yes | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | No symptoms | Additional Testing | ALT: 145 U/L; AST: 57 U/L; Bilirubin: 10.9 umol/L; Serum Creatinine: 63 umol/dL | 9-Jan-15 | Hepatitis Serology Result | None | |||||||||||||||
| DLS14-08007 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 6.00 | $65.00 | 28 Y | F | Asian | < -70C | 14-Nov-14 | Roche cobas | 35,400,000 copies/mL | 7-Nov-14 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Transfusion | Symptoms | Fatigue | Additional Testing | ALT: 52 U/L; AST: 92 U/L; ALP : 92 U/L; Bilirubin: 17 umol/L; Serum Creatinine: 70 umol/L | 5-Nov-14 | Hepatitis Serology Result | None | |||||||||||||||
| DLS14-08054 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 10.00 | $65.00 | 38 Y | M | Asian | < -70C | 02-Feb-15 | Roche cobas | 3,050,000 copies/mL | 7-Oct-14 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir 300 mg; Lamivudine 300 mg; Efavirenz 600 mg | Acquired Infection Category | IV Drug Abuse | Symptoms | No symptoms | Additional Testing | ALT: 47 U/L; AST: 62 U/L; Serum Creatinine: 84 umol/dL | 13-Jan-15 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 28-Oct-2014 | Co-Infections | HIV Positive | 10-Oct-14 | |||||||||||
| DLS14-07992 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 5.00 | $65.00 | 30 Y | M | Asian | <-70°C | 05-Mar-15 | Roche cobas | 1,360 IU/mL | 4-Mar-15 | $65.00 | 3-series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 563 U/L; AST: 922 U/L; Bilirubin: 394 umol/L; Serum Creatinine: 79.8 umol/L | 12-Feb-15 | Hepatitis Serology Result | None | ||||||||||||||||
| DLS14-08013 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 14.00 | $65.00 | 49 Y | F | Asian | <-70°C | 20-Mar-15 | Roche cobas | 2,000,000 IU/mL | 10-Mar-15 | $65.00 | 3-series HepB Vaccine | Partial | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 5 U/L; AST: 35 U/L; Bilirubin: 6.3 umol/L; Serum Creatinine: 48 umol/L | 20-Mar-15 | Hepatitis Serology Result | None | ||||||||||||||||
| DLS14-08049 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 10.00 | $65.00 | 49 Y | F | Asian | <-70°C | 12-Feb-15 | Roche cobas | 5,500,000 copies/mL | 5-Feb-15 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Acquired Infection Category | Sexual Transmission | Symptoms | Decreased Appetite; Fatigue; Abdominal Pain | Additional Testing | ALT: 298 U/L; AST: 135 U/L; Serum Creatinine: 58 umol/L | 16-Dec-14 | Hepatitis Serology Result | HBsAg -; Anti HCV + (Elisa) | 16-Dec-14 | |||||||||||||||
| DLS15-34152 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 37 Y | M | U/A | <-70°C | 02-Jul-15 | Roche cobas | 3,821,825 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34153 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.50 | 1.00 | $65.00 | 47 Y | M | U/A | <-70°C | 20-Jul-15 | Roche cobas | 2,277,300 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34155 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 2.00 | $65.00 | 57 Y | M | U/A | <-70°C | 30-Jun-15 | Roche cobas | 2,559,498 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34156 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 3.00 | $65.00 | 51 Y | M | U/A | <-70°C | 20-Jul-15 | Roche cobas | 1,265,458 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34157 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 47 Y | M | U/A | <-70°C | 01-Jul-15 | Roche cobas | 3,508,725 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34158 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 46 Y | F | U/A | <-70°C | 20-Jul-15 | Roche cobas | 820,523 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34159 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 3.00 | $65.00 | 55 Y | F | U/A | <-70°C | 18-Jul-15 | Roche cobas | 1,496,422 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34160 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 2.00 | $65.00 | 39 Y | M | U/A | <-70°C | 18-Jul-15 | Roche cobas | 674,198 IU/mL | HCV | Roche cobas TaqMan HCV test, v2.0 | 367,240 U/mL | Hepatitis C Virus RNA Qt 04/08/2019 8:34 | Roche cobas TaqMan HCV test, v2.0 | 5.56 LogUnit/mL | Hepatitis C Virus RNA Log10 04/08/2019 8:34 | $65.00 | |||||||||||||||||||||||
| DLS15-34162 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 63 Y | M | U/A | <-70°C | 30-Jun-15 | Roche cobas | 194,632 IU/mL | HCV | Roche cobas TaqMan HCV test, v2.0 | 139,164 U/mL | Hepatitis C Virus RNA Qt 04/08/2019 8:34 | Roche cobas TaqMan HCV test, v2.0 | 5.14 LogUnit/mL | Hepatitis C Virus RNA Log10 04/08/2019 8:34 | $65.00 | |||||||||||||||||||||||
| DLS15-34164 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 2.00 | $65.00 | 61 Y | F | U/A | <-70°C | 01-Jul-15 | Roche cobas | 1,101,915 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34165 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 2.00 | $65.00 | 41 Y | F | U/A | <-70°C | 17-Jul-15 | Roche cobas | 3,142,779 IU/mL | HCV | Roche cobas TaqMan HCV test, v2.0 | 2,081,907 U/mL | Hepatitis C Virus RNA Qt 04/08/2019 8:34 | Roche cobas TaqMan HCV test, v2.0 | 6.32 LogUnit/mL | Hepatitis C Virus RNA Log10 04/08/2019 8:34 | $65.00 | |||||||||||||||||||||||
| DLS15-34167 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 2.00 | $65.00 | 50 Y | M | U/A | <-70°C | 21-Jul-15 | Roche cobas | 1,778,924 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34168 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 3.00 | $65.00 | 62 Y | M | U/A | <-70°C | 20-Jul-15 | Roche cobas | 1,063,739 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34169 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 50 Y | M | U/A | <-70°C | 06-Aug-15 | Roche cobas | 2,317,000 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34170 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 3.00 | $65.00 | 57 Y | F | U/A | <-70°C | 06-Aug-15 | Roche cobas | 1,444,340 IU/mL | HCV | Roche cobas TaqMan HCV test, v2.0 | 1,259,324 U/mL | Hepatitis C Virus RNA Qt 04/08/2019 8:34 | Roche cobas TaqMan HCV test, v2.0 | 6.10 LogUnit/mL | Hepatitis C Virus RNA Log10 04/08/2019 8:34 | $65.00 | |||||||||||||||||||||||
| DLS15-34171 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 0.75 | 1.00 | $65.00 | 53 Y | M | U/A | <-70°C | 06-Aug-15 | Roche cobas | 340,068 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34172 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 2.00 | $65.00 | 67 Y | M | U/A | <-70°C | 06-Aug-15 | Roche cobas | 1,678 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34174 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 68 Y | M | U/A | <-70°C | 21-Jul-15 | Roche cobas | 7,132,610 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS15-34175 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 2.00 | $65.00 | 63 Y | M | U/A | <-70°C | 06-Aug-15 | Roche cobas | 2,077,381 IU/mL | HCV | $65.00 | |||||||||||||||||||||||||||||
| DLS14-12455-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 3.00 | $45.00 | 41 Y | M | Black | <-70C | 02-Mar-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Weight loss; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Elevated LFTs | Risk Categories | Homosexual M; Intravenous drug user; Body punctures | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12463-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 7.00 | $45.00 | 49 Y | F | Black | <-70C | 09-May-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Weight loss; Fatigue; Nausea; Vomiting; Abdominal pains; Fever / chills; Dark color urine / light color feces; Elevated LFTs | Risk Categories | Sexual contacts of HBV or HCV infected person; Sexually transmitted diseases (STD); Intravenous drug user; Body punctures (Tattooing); Household contacts of HBV or HCV infected person | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12463-S | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $45.00 | 49 Y | F | Black | <-70C | 09-May-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Weight loss; Fatigue; Nausea; Vomiting; Abdominal pains; Fever / chills; Dark color urine / light color feces; Elevated LFTs | Risk Categories | Sexual contacts of HBV or HCV infected person; Sexually transmitted diseases (STD); Intravenous drug user; Body punctures (Tattooing); Household contacts of HBV or HCV infected person | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12470-P | Hepatitis C (HCV) | Mexico | Plasma | 1.00 | 6.00 | $45.00 | 57 Y | F | U/A | <-70C | 01-Oct-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Jaundice; Nausea; Vomiting; Abdominal pains; Dark color urine / light color feces; Elevated LFTs | Risk Categories | Multiple sex partners; Transplant / transfusion of unscreened blood or blood products (prior to 1992) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12470-S | Hepatitis C (HCV) | Mexico | Serum | 1.00 | 1.00 | $45.00 | 57 Y | F | U/A | <-70C | 01-Oct-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Jaundice; Nausea; Vomiting; Abdominal pains; Dark color urine / light color feces; Elevated LFTs | Risk Categories | Multiple sex partners; Transplant / transfusion of unscreened blood or blood products (prior to 1992) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12474-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 53 Y | F | Black | <-70C | 19-Oct-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Abdominal pains; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD); Intravenous drug user; Multiple sex partners; Body punctures (Piercing) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12477-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 41 Y | F | Black | <-70C | 10-Sep-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD)'; Intravenous drug user; Body punctures (Tattooing) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12481-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 42 Y | F | Black | <-70C | 19-Oct-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Weight loss; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Dark color urine / light color feces; Elevated LFTs | Risk Categories | Occupational contact with blood (Medical or dental workers); Body punctures (Acupuncture, Pierciing) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12488-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 4.00 | $45.00 | 54 Y | M | Black | <-70C | 23-Aug-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Muscle or joint aches (Myalgia); Elevated LFTs | Risk Categories | Multiple sex partners | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12490-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 37 Y | M | White | <-70C | 13-Sep-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Nausea; Light color feces; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD); Multiple sex partners; Institutionalized population | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12491-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 59 Y | M | Black | <-70C | 17-Sep-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Fatigue; Nausea; Light color feces; Elevated LFTs | Risk Categories | Sexual contacts of HBV or HCV infected person; Sexually transmitted diseases (STD); Intravenous drug user; Multiple sex partners; Institutionalized population (Past) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12492-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 7.00 | $45.00 | 30 Y | F | White | <-70C | 09-Oct-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Fatigue; Dark color urine; Elevated LFTs | Risk Categories | Multiple sex partners; Body punctures, (Tattooing & piercing); Pregnant (4.5 months) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12494-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 7.00 | $45.00 | 56 Y | F | Black | <-70C | 08-Feb-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Abdominal pains; Muscle or joint aches (Myalgia); Dark color urine / light color feces; Elevated LFTs | Risk Categories | Occupational contact with blood (Medical or dental workers); Body punctures (Piercing) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12495-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 56 Y | M | Black | <-70C | 29-Jan-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD); Intravenous drug user; Institutionalized population | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12495-S | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $45.00 | 56 Y | M | Black | <-70C | 29-Jan-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD); Intravenous drug user; Institutionalized population | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12504-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 7.00 | $45.00 | 57 Y | M | Black | <-70C | 15-Nov-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Fatigue; Dark color urine / light color feces; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD); Homosexual M; Body punctures (Human bite); Haemodialysis patient | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12505-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 45 Y | F | Black | <-70C | 30-Oct-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Dark color urine / light color feces; Elevated LFTs | Risk Categories | Body punctures (Piercing); Household contacts of HBV or HCV infected person | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12505-S | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $45.00 | 45 Y | F | Black | <-70C | 30-Oct-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Dark color urine / light color feces; Elevated LFTs | Risk Categories | Body punctures (Piercing); Household contacts of HBV or HCV infected person | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12506-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 7.00 | $45.00 | 53 Y | F | Black | <-70C | 12-Nov-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Fatigue; Abdominal pains; Muscle or joint aches (Myalgia); Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD); Intravenous drug user; Multiple sex partners; Body punctures (Tattooing, piercing); Haemodialysis patient | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12507-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 5.00 | $45.00 | 61 Y | M | Black | <-70C | 06-Dec-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Dark color urine / light color feces; Elevated LFTs | Risk Categories | Sexual contacts of HBV or HCV infected person; Intravenous drug user; Multiple sex partners | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12509-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 7.00 | $45.00 | 49 Y | F | Black | <-70C | 16-Nov-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Weight loss; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Elevated LFTs | Risk Categories | Sexually transmited diseases (STD); Body punctures (Piercing); Haemodialysis patient | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12509-S | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $45.00 | 49 Y | F | Black | <-70C | 16-Nov-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Weight loss; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Elevated LFTs | Risk Categories | Sexually transmited diseases (STD); Body punctures (Piercing); Haemodialysis patient | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12513-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 7.00 | $45.00 | 55 Y | F | Black | <-70C | 05-Nov-12 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Dark color urine / light color feces; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD); Multiple sex partners; Body punctures (Piercing); Institutionalized population | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12527-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 5.00 | $45.00 | 40 Y | M | White | <-70C | 12-Aug-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Fatigue; Dark color urine; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD); Intravenous drug user; Body punctures, (Human bite) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12532-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 50 Y | M | Black | <-70C | 02-Apr-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Chills; Dark color urine; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD); Homosexual M; Multiple sex partners; Transfusion of unscreened blood or blood products (prior to 1992) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12534-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 44 Y | M | Black | <-70C | 20-Jun-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Weight loss; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Dark color urine / light color feces; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12537-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 5.00 | $45.00 | 57 Y | M | Black | <-70C | 03-Jun-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Elevated LFTs | Risk Categories | Intravenous drug user | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12539-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 5.00 | $45.00 | 48 Y | F | Black | <-70C | 30-Apr-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Weight loss; Fatigue; Vomiting; Abdominal pains; Elevated LFTs | Risk Categories | Sexual contacts of HBV or HCV infected person; Body punctures (Piercing, human bite) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12540-P | Hepatitis C (HCV) | Mexico | Plasma | 1.00 | 6.00 | $45.00 | 30 Y | M | U/A | <-70C | 12-Apr-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Fatigue; Elevated LFTs | Risk Categories | Intravenous drug user; Body punctures | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12550-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 26 Y | F | White | <-70C | 15-May-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Muscle or joint aches (Myalgia); Elevated LFTs | Risk Categories | Transplant / transfusion of blood or blood products (prior to 1992) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12551-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 31 Y | F | White | <-70C | 03-Jun-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Jaundice; Fatigue; Abdominal pains; Dark color urine; Elevated LFTs | Risk Categories | Sexual contacts of HBV or HCV infected person; Body punctures; Household contacts of HBV or HCV infected person | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12552-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 5.00 | $45.00 | 22 Y | F | White | <-70C | 04-Jun-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Fatigue; Nausea; Abdominal pains; Muscle or joint aches (Myalgia); Elevated LFTs | Risk Categories | Intravenous drug user; Body punctures (Piercing) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12554-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 5.00 | $45.00 | 46 Y | M | White | <-70C | 20-Jun-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Light color feces (Diarrhea); Elevated LFTs | Risk Categories | Intravenous drug user | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12558-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 6.00 | $45.00 | 23 Y | F | Black | <-70C | 16-Jul-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD); Multiple sex partners; Body punctures (Tattooing, piercing, human bite) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12566-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 7.00 | $45.00 | 57 Y | F | Black | <-70C | 14-Aug-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Fever / chills; Dark color urine / light color feces; Elevated LFTs | Risk Categories | Body punctures (Piercing); Transfusion of unscreened blood or blood products (prior to 1992) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12567-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 5.00 | $45.00 | 57 Y | F | Black | <-70C | 08-Oct-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Weight loss; Fatigue; Muscle or joint aches (Myalgia); Light color feces; Elevated LFTs | Risk Categories | Sexually transmitted diseases (STD); Intravenous drug user; Body punctures; Institutionalized population | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-12573-P | Hepatitis C (HCV) | USA | Plasma | 1.00 | 5.00 | $45.00 | 58 Y | F | Black | <-70C | 26-Aug-13 | Ortho HCV 3.0 ELISA | Reactive | HCV Ab | $45.00 | Signs & Symptoms | Loss of appetite; Weight loss; Fatigue; Nausea; Vomiting; Abdominal pains; Muscle or joint aches (Myalgia); Chills; Elevated LFTs | Risk Categories | Intravenous drug user; Body punctures (Tattooing, piercing; human bite); Institutionalized population (Prisoner) | Bio-Rad GD HBsAg EIA 3.0 | Negative | MONOLISA Anti-HBC IgM EIA | Negative | |||||||||||||||||||||
| DLS14-07979 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 10.00 | $65.00 | 52 Y | M | Asian | <-70°C | 13-May-15 | Roche cobas | 97,600 IU/mL | 4-May-15 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | |||||||||||||||||||||
| DLS14-08000 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 9.00 | $65.00 | 38 Y | F | Asian | <-70°C | 12-May-15 | Roche cobas | 5,050,000 copies/mL | 26-Apr-15 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | |||||||||||||||||||||
| DLS14-08020 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 6.00 | $65.00 | 23 Y | M | Asian | <-70°C | 12-May-15 | Roche cobas | 5,400 IU/mL | 8-Mar-15 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Jaundice | |||||||||||||||||||||
| DLS14-21266 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 10.00 | $65.00 | 48 Y | M | Asian | <-70°C | 27-Nov-15 | Real-Time PCR | Unknown | HCV | $65.00 | Signs and Symptoms | No symptoms | |||||||||||||||||||||||||||
| DLS16-11777-K2 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 8.00 | $65.00 | 33 Y | M | White | <-70C | 11-Jan-16 | Abbott Prism | Positive | HCV Ab | $65.00 | Roche cobas TaqScreen | Positive HCV | Arlington Scientific Card Test | Negative | RPR | Smoke | Yes | Blood Type | O+ | Abbott Prism | Negative | HBsAg, Anti-HIV I/II | Roche cobas TaqScreen | Negative | HIV, HBV | ||||||||||||||
| DLS16-67429 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 17.00 | $65.00 | 52 Y | F | Asian | <-70°C | 01-Nov-16 | Roche cobas | 11,700 IU/mL | 26-Oct-16 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 79 U/L; AST: 307 U/L; Bilirubin: 38.6 umol/L; Serum Creatinine: 77 umol/L | 31-Oct-16 | Hepatitis Serology | HCV Ab + (cobas 6000E) | 21-Oct-16 | Co-Infections | N/A | |||||||||||||
| DLS16-67466 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 9.00 | $65.00 | 44 Y | M | Asian | <-70°C | 16-Nov-16 | Roche cobas | 1,170,000 IU/mL | 15-Nov-16 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Abdominal pain; Jaundice | Additional Testing | ALT: 26 U/L; AST: 22 U/L | 13-Nov-16 | Hepatitis Serology | HCV Ab + (cobas 6000E) | Sep-16 | Co-Infections | N/A | |||||||||||||
| DLS16-67501 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 16.00 | $65.00 | 46 Y | M | Asian | <-70°C | 18-Nov-16 | Roche HCV Monitor | 230,000 copies/mL | 16-Nov-16 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | Yes | Tenofovir; Lamivudine; Efavirenz | Acquired Infection Category | Sexual Transmission | Symptoms | Fatigue; Jaundice; Itching; Sleep disturbances | Additional Testing | ALT: 50 U/L; AST: 56 U/L; Serum Creatinine: 86 umol/L | 9-Jul-16 | Hepatitis Serology | N/A | Co-Infections | HIV+ | Jun-05 | ||||||||||||
| DLS16-67571 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 14.00 | $65.00 | 52 Y | F | Asian | <-70°C | 24-Nov-16 | Roche HCV Monitor | 11,700 IU/mL | 21-Nov-16 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue; Abdominal pain; Jaundice | Additional Testing | ALT: 833 U/L; AST: 1301 U/L; Bilirubin: 137.8 umol/L; Serum Creatinine: 68 umol/L | 15-Nov-16 | Hepatitis Serology | HCV Ab + (cobas 6000E) | 10-Nov-16 | Co-Infections | N/A | |||||||||||||
| DLS16-67611 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 18.00 | $65.00 | 54 Y | M | Asian | <-70°C | 24-Nov-16 | Roche cobas | 120,000 IU/mL | 21-Nov-16 | $65.00 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 63 U/L; AST: 46 U/L; Bilirubin: 18 umol/L; Serum Creatinine: 83 umol/L | 21-Nov-16 | Hepatitis Serology | HCV Ab + (cobas 6000E) | 21-Nov-16 | Co-Infections | N/A | |||||||||||||
| DLS16-67564 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 2.00 | $65.00 | 39 Y | M | Asian | <-70C | 14-Apr-17 | Roche Cobas | 26,000,000 IU/mL | HCV Ab | $65.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | IV Drug Abuse | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 82 U/L, AST: 67 U/L, Bilirubin: 82 umol/L, Serum Creatinine: 72 umol/L, Chronic HCV | 10-Apr-2017 | Hepatitis Serology | HCV Ab + | Co-Infections | AIDS+ | Dec-16 | ||||||||||||
| DLS16-67599 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 4.00 | $65.00 | 54 Y | M | Asian | <-70C | 24-Feb-17 | Roche Cobas | 1,490,000 IU/mL | HCV Ab | $65.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Fatigue; Jaundice | Additional Testing | ALT: 80 U/L , AST: 118 U/L, Bilirubin: 8 umol/L, Serum Creatinine: 69 umol/L, HCV 2017 | 21-Feb-2017 | Hepatitis Serology | Anti HCV + | Co-Infections | None | |||||||||||||
| DLS16-67645 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 3.00 | $65.00 | 36 Y | M | Asian | <-70C | 06-Mar-17 | Roche Cobas | 400 IU/mL | HCV Ab | $65.00 | 3-Series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | No | None | Acquired Infection Category | Unknown | Symptoms | Decreased appetite; Fatigue | Additional Testing | ALT: 51 U/L, AST: 32 U/L, ALP: 85 U/L, LDH: 150 U/L, Bilirubin: 32.6 umol/L, Chronic HCV 2016 | 2-Mar-2017 | Hepatitis Serology | None | Co-Infections | None | |||||||||||||
| DLS14-12576 | Hepatitis C (HCV) | USA | K2 EDTA | 5.00 | 24.00 | $45.00 | M | U/A | <-70C | 25-Mar-08 | Roche COBAS AmpliScreen HCV | Positive | HCV Ab | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | ||||||||||||||||||||||||||
| DLS14-12577 | Hepatitis C (HCV) | USA | Serum | 5.00 | 16.00 | $45.00 | 38 Y | M | White | <-70C | 30-Dec-08 | Roche COBAS AmpliScreen HCV | Positive | HCV AB | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12578 | Hepatitis C (HCV) | USA | Na2 | 5.00 | 32.00 | $45.00 | 28 Y | M | White | <-70C | 08-Apr-09 | Roche COBAS AmpliScreen HCV | Positive | HCV Ab | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12579 | Hepatitis C (HCV) | USA | Serum | 5.00 | 13.00 | $45.00 | 27 Y | M | Hispanic | <-70C | 13-May-09 | Roche COBAS AmpliScreen HCV | Positive | HCV AB | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12580 | Hepatitis C (HCV) | USA | Na Cit | 5.00 | 30.00 | $45.00 | 38 Y | M | Black | <-70C | 18-May-09 | Roche COBAS AmpliScreen HCV | Positive | HCV Ab | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12581 | Hepatitis C (HCV) | USA | Serum | 5.00 | 11.00 | $45.00 | 33 Y | F | White | <-70C | 24-Jun-09 | Roche COBAS AmpliScreen HCV | Positive | HCV AB | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12582 | Hepatitis C (HCV) | USA | Serum | 5.00 | 28.00 | $45.00 | M | U/A | <-70C | 13-Jul-09 | Roche COBAS AmpliScreen HCV | Positive | HCV Ab | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | ||||||||||||||||||||||||||
| DLS14-12583 | Hepatitis C (HCV) | USA | Serum | 5.00 | 18.00 | $45.00 | 18 Y | M | White | <-70C | 15-Jul-09 | Roche COBAS AmpliScreen HCV | Positive | HCV Ab | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12584 | Hepatitis C (HCV) | USA | Serum | 5.00 | 13.00 | $45.00 | M | U/A | <-70C | 12-Aug-09 | Roche COBAS AmpliScreen HCV | Positive | HCV Ab | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | ||||||||||||||||||||||||||
| DLS14-12585 | Hepatitis C (HCV) | USA | Serum | 5.00 | 17.00 | $45.00 | 36 Y | M | Hispanic | <-70C | 30-Jul-09 | Roche COBAS AmpliScreen HCV | Positive | HCV AB | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12586 | Hepatitis C (HCV) | USA | Serum | 5.00 | 24.00 | $45.00 | 39 Y | M | Black | <-70C | 15-Sep-09 | Roche COBAS AmpliScreen HCV | Positive | HCV AB | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12587 | Hepatitis C (HCV) | USA | K3 EDTA | 5.00 | 43.00 | $45.00 | 34 Y | F | Black | <-70C | 27-Apr-07 | Roche COBAS AmpliScreen HCV | Positive | HCV Ab | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12588 | Hepatitis C (HCV) | USA | Serum | 5.00 | 11.00 | $45.00 | 47 Y | M | Black | <-70C | 30-Jun-09 | Roche COBAS AmpliScreen HCV | Positive | HCV AB | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12589 | Hepatitis C (HCV) | USA | K2 EDTA | 5.00 | 20.00 | $45.00 | 23 Y | M | White | <-70C | 01-Dec-09 | Roche COBAS AmpliScreen HCV | Positive | HCV Ab | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12590 | Hepatitis C (HCV) | USA | Serum | 5.00 | 9.00 | $45.00 | 35 Y | M | Black | <-70C | 01-Dec-09 | Roche COBAS AmpliScreen HCV | Positive | HCV AB | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12591 | Hepatitis C (HCV) | USA | K3 EDTA | 5.00 | 16.00 | $45.00 | 33 Y | M | White | <-70C | 08-Mar-10 | Roche COBAS AmpliScreen HCV | Positive | HCV Ab | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS14-12592 | Hepatitis C (HCV) | USA | Serum | 5.00 | 11.00 | $45.00 | 31 Y | M | White | <-70C | 15-Apr-10 | Roche COBAS AmpliScreen HCV | Positive | HCV Ab | $45.00 | Roche cobas TaqScreen MPX | Reactive | Abbott PRISM | Non Reactive | |||||||||||||||||||||||||
| DLS16-67470 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 6.00 | $65.00 | 32 Y | M | Asian | <-70C | 22-May-17 | Roche Cobas | 160,000 IU/mL | HCV Ab | $65.00 | Real Time PCR | Not Detected | 22-May-17 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | U/A | Symptoms | Abdominal pain; Fatigue; Jaundice | Additional Testing | ALT: 47 U/L | AST: 62 U/L | Serum Creatinine: 73 umol/L | 22-May-17 | Hepatitis Serology | HCV Ab + | COBAS 6000E | 21-May-2017 | ||||||||||||
| DLS16-67462 | Hepatitis C (HCV) | Vietnam | Serum | 1.00 | 8.00 | $65.00 | 45 Y | M | Asian | <-70C | 12-May-17 | Roche Cobas | 45,000 IU/mL | HCV Ab | $65.00 | Real Time PCR | Not Detected | 23-May-17 | 3-series HepB Vaccine | No | Is Subject on Anti-Viral Therapy / Treatment | None | Acquired Infection Category | U/A | Symptoms | Fatigue; Sleep disturbances | Additional Testing | ALT: 25 U/L | AST: 32 U/L | Serum Creatinine: 65 umol/L | 3-May-17 | Hepatitis Serology | HCV Ab + | COBAS 6000E | 3-May-2017 | ||||||||||||
| KH18-10933 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 63 Y | M | Black | <-70C | 13-Feb-18 | PCR | Positive | HCV | $65.00 | RNA | 4,956, 831 | |||||||||||||||||||||||||||
| KH18-10934 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 58 Y | M | White | <-70C | 13-Feb-18 | PCR | Positive | HCV | $65.00 | RNA | 30,320,956 | |||||||||||||||||||||||||||
| DLS0000101 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 20 Y | F | U/A | <-70C | 09-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | $100.00 | |||||||||||||||||||||||||||||
| DLS0002281 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 39 Y | F | U/A | <-70C | 09-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | $100.00 | |||||||||||||||||||||||||||||
| DLS0019809 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 94 Y | F | U/A | <-70C | 08-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.414 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.0581 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | U/A | C. Trachomatis | U/A | |||||||||||||
| DLS0003178 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $100.00 | 27 Y | F | U/A | <-70C | 08-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 30.1 | Anti HSV 2 IgG | Positive | Anti HSV 2 IgG Quantitative | 6.12 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | |||||||||||||
| DLS0019903 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 30 Y | F | U/A | <-70C | 06-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 47.0 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.0653 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | U/A | C. Trachomatis | Not Detected | |||||||||||||
| DLS0002495 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 28 Y | F | U/A | <-70C | 09-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.139 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.0811 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | |||||||||||||
| DLS0020153 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 38 Y | F | U/A | <-70C | 06-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 14.4 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.132 | N. Gonorrhoeae | U/A | Treponema pallidum ab | Negative | C. Trachomatis | U/A | |||||||||||||||
| DLS0002601 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 25 Y | F | U/A | <-70C | 06-Mar-18 | Roche cobas 602 | ECLIA | 0.03 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.101 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.198 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | |||||||||||||
| DLS0019687 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 21 Y | F | U/A | <-70C | 07-Mar-18 | Roche cobas 602 | ECLIA | 0.03 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 37.3 | Anti HSV 2 IgG | Positive | Anti HSV 2 IgG Quantitative | 1.15 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | |||||||||||||
| DLS0000372 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 42 Y | F | U/A | <-70C | 07-Mar-18 | Roche cobas 602 | ECLIA | 0.03 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 15.1 | Anti HSV 2 IgG | Positive | Anti HSV 2 IgG Quantitative | 1.91 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | |||||||||||||
| DLS0002905 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 51 Y | M | U/A | <-70C | 07-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 44.2 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.0954 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | |||||||||||||
| KH18-12849 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 54 Y | M | White | <-70C | 14-Dec-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 7,369,037 | |||||||||||||||||||||||||||
| KH18-12850 | Hepatitis C (HCV) | USA | Serum | 1.75 | 1.00 | $65.00 | 67 Y | M | Black | <-70C | 19-Feb-18 | PCR | Positive | HCV | $65.00 | RNA Quant: | 9,282,060 | |||||||||||||||||||||||||||
| KH18-12851 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 59 Y | F | Black | <-70C | 14-Mar-18 | PCR | Positive | HCV | $65.00 | RNA Quant: | 3,998,420 | |||||||||||||||||||||||||||
| KH18-12852 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 33 Y | F | White | <-70C | 21-Dec-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 3,201,778 | |||||||||||||||||||||||||||
| KH18-12853 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 63 Y | M | White | <-70C | 28-Dec-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 3,256,645 | |||||||||||||||||||||||||||
| KH18-12854 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 31 Y | M | American Indian | <-70C | 07-Dec-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 493 | |||||||||||||||||||||||||||
| KH18-12855 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 59 Y | M | Black | <-70C | 28-Nov-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 1,759,606 | |||||||||||||||||||||||||||
| KH18-12856 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 49 Y | M | White | <-70C | 28-Nov-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 135 | |||||||||||||||||||||||||||
| KH18-12857 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 63 Y | M | Black | <-70C | 29-Nov-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 3,068,549 | |||||||||||||||||||||||||||
| KH18-12858 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 61 Y | M | Black | <-70C | 06-Oct-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 5,716,504 | |||||||||||||||||||||||||||
| KH18-12861 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 50 Y | M | White | <-70C | 02-Jul-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 935,341 | |||||||||||||||||||||||||||
| KH18-12865 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 41 Y | M | White | <-70C | 12-Oct-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 21,448 | |||||||||||||||||||||||||||
| KH18-12866 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 58 Y | M | Black | <-70C | 07-Sep-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 1,210,800 | |||||||||||||||||||||||||||
| KH18-12868 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 57 Y | F | Black | <-70C | 07-Jul-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 658,254 | |||||||||||||||||||||||||||
| KH18-12869 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 63 Y | F | Black | <-70C | 31-Oct-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 252,621 | |||||||||||||||||||||||||||
| KH18-12870 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 34 Y | F | White | <-70C | 29-Nov-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 2,681 | |||||||||||||||||||||||||||
| KH18-12871 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 39 Y | M | Black | <-70C | 05-Sep-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 755,739 | |||||||||||||||||||||||||||
| KH18-12872 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 56 Y | M | White | <-70C | 05-Sep-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 4,.339,277 | |||||||||||||||||||||||||||
| KH18-12873 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 52 Y | M | White | <-70C | 01-Sep-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 242,154 | |||||||||||||||||||||||||||
| KH18-12875 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 35 Y | F | White | <-70C | 17-Oct-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 99,538 | |||||||||||||||||||||||||||
| KH18-12876 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 55 Y | M | U/A | <-70C | 12-Sep-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 11,225,008 | |||||||||||||||||||||||||||
| KH18-12877 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 35 Y | F | White | <-70C | 19-Jul-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 21,559 | |||||||||||||||||||||||||||
| KH18-12879 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 47 Y | F | White | <-70C | 30-Jun-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 765 | |||||||||||||||||||||||||||
| KH18-12880 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 64 Y | F | White | <-70C | 06-Jul-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 2,102,282 | |||||||||||||||||||||||||||
| KH18-12881 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 47 Y | F | U/A | <-70C | 07-Jul-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 313,876 | |||||||||||||||||||||||||||
| KH18-12882 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 62 Y | M | White | <-70C | 22-Sep-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 1,165,592 | |||||||||||||||||||||||||||
| KH18-12883 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 64 Y | F | Black | <-70C | 19-Nov-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 375,038 | |||||||||||||||||||||||||||
| KH18-12885 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 51 Y | F | White | <-70C | 13-Nov-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 32 | |||||||||||||||||||||||||||
| KH18-12886 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 63 Y | F | White | <-70C | 06-Jul-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 7,951,053 | |||||||||||||||||||||||||||
| KH18-12887 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 34 Y | M | Black | <-70C | 05-Oct-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 531,066 | |||||||||||||||||||||||||||
| KH18-12888 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 62 Y | M | White | <-70C | 13-Jul-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 1,691,533 | |||||||||||||||||||||||||||
| KH18-12889 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 24 Y | M | White | <-70C | 24-Sep-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 1,848,790 | |||||||||||||||||||||||||||
| KH18-12890 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 64 Y | M | Black | <-70C | 05-Sep-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 3,698,809 | |||||||||||||||||||||||||||
| KH18-12891 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 58 Y | F | White | <-70C | 14-Oct-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 418,462 | |||||||||||||||||||||||||||
| KH18-12892 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 56 Y | M | White | <-70C | 05-Sep-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 4,339,277 | |||||||||||||||||||||||||||
| KH18-12894 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 84 Y | F | Black | <-70C | 06-Jul-17 | PCR | Positive | HCV | $65.00 | RNA Quant: | 4,918,625 | |||||||||||||||||||||||||||
| DLS0017731 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 56 Y | F | U/A | <-70C | 09-Mar-18 | Roche cobas 602 | ECLIA | 0.03 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 30.6 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.0801 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0019211 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 52 Y | F | U/A | <-70C | 09-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 26.6 | Anti HSV 2 IgG | Positive | Anti HSV 2 IgG Quantitative | 3.37 | N. Gonorrhoeae | U/A | Treponema pallidum ab | Negative | C. Trachomatis | U/A | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0019138 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 41 Y | F | U/A | <-70C | 15-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 34.6 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.164 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0019191 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 51 Y | F | U/A | <-70C | 15-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 35.5 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.259 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0019422 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $100.00 | 24 Y | F | U/A | <-70C | 15-Mar-18 | Roche cobas 602 | ECLIA | 0.03 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.0113 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.110 | N. Gonorrhoeae | U/A | Treponema pallidum ab | U/A | C. Trachomatis | U/A | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0019255 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 24 Y | F | U/A | <-70C | 12-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 5.39 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.138 | N. Gonorrhoeae | U/A | Treponema pallidum ab | Negative | C. Trachomatis | U/A | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0017408 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 20 Y | F | U/A | <-70C | 12-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 50.5 | Anti HSV 2 IgG | Positive | Anti HSV 2 IgG Quantitative | 6.86 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0019181 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 16 Y | F | U/A | <-70C | 13-Mar-18 | Roche cobas 602 | ECLIA | 0.03 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.0730 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.0879 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0019050 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 40 Y | F | U/A | <-70C | 13-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 31.3 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.158 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0019803 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $100.00 | 52 Y | F | U/A | <-70C | 16-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 34.3 | Anti HSV 2 IgG | Positive | Anti HSV 2 IgG Quantitative | 2.32 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0002815 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $100.00 | 22 Y | F | U/A | <-70C | 16-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.0512 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.0729 | N. Gonorrhoeae | U/A | Treponema pallidum ab | Negative | C. Trachomatis | U/A | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0018879 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 29 Y | F | U/A | <-70C | 16-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | <0.0100 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.0532 | N. Gonorrhoeae | U/A | Treponema pallidum ab | Negative | C. Trachomatis | U/A | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0002447 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $100.00 | 29 Y | F | U/A | <-70C | 23-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | $100.00 | |||||||||||||||||||||||||||
| DLS0003641 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 55 Y | F | U/A | <-70C | 23-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | $100.00 | |||||||||||||||||||||||||||
| DLS0003285 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 56 Y | F | U/A | <-70C | 22-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 1.19 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.174 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0019697 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $100.00 | 30 Y | F | U/A | <-70C | 22-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 1.27 | Anti HSV 2 IgG | Positive | Anti HSV 2 IgG Quantitative | 10.2 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0002577 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $100.00 | 21 Y | F | U/A | <-70C | 19-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 30.9 | Anti HSV 2 IgG | Positive | Anti HSV 2 IgG Quantitative | 2.02 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0019571 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $100.00 | 21 Y | F | U/A | <-70C | 19-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.123 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.17 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0002851 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 40 Y | F | U/A | <-70C | 20-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 21.4 | Anti HSV 2 IgG | Positive | Anti HSV 2 IgG Quantitative | 7.86 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0020187 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $100.00 | 46 Y | F | U/A | <-70C | 19-Mar-18 | Roche cobas 602 | ECLIA | 0.03 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 50.6 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.0851 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0003437 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $100.00 | 54 Y | M | U/A | <-70C | 20-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.135 | Anti HSV 2 IgG | Positive | Anti HSV 2 IgG Quantitative | 4.11 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | U/A | |||||||||||
| DLS0000516 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $100.00 | 17 Y | F | U/A | <-70C | 23-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 1.52 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.220 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0002627 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 66 Y | F | U/A | <-70C | 29-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 41.5 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.579 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0000144 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $100.00 | 18 Y | F | U/A | <-70C | 28-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.108 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.190 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0002188 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 34 Y | M | U/A | <-70C | 23-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.0764 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.144 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0003763 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 39 Y | F | U/A | <-70C | 30-Mar-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 31.1 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.118 | N. Gonorrhoeae | U/A | Treponema pallidum ab | Negative | C. Trachomatis | U/A | HIV 1| 2 Ag|Ab Combo | U/A | |||||||||||
| DLS0003309 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 29 Y | F | U/A | <-70C | 06-Apr-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | U/A | $100.00 | Anti HSV 1 IgG Quantitative | U/A | Anti HSV 2 IgG | U/A | Anti HSV 2 IgG Quantitative | U/A | N. Gonorrhoeae | U/A | Treponema pallidum ab | U/A | C. Trachomatis | U/A | HIV 1| 2 Ag|Ab Combo | U/A | |||||||||||
| DLS0004401 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 32 Y | F | U/A | <-70C | 05-Apr-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | U/A | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 47.8 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.0987 | N. Gonorrhoeae | U/A | Treponema pallidum ab | Negative | C. Trachomatis | U/A | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0003673 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 17 Y | F | U/A | <-70C | 05-Apr-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.337 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.26 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0004374 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $100.00 | 26 Y | F | U/A | <-70C | 05-Apr-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Positive | $100.00 | Anti HSV 1 IgG Quantitative | 50.1 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.0681 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0004533 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $100.00 | 21 Y | F | U/A | <-70C | 04-Apr-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.177 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.468 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| DLS0004621 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $100.00 | 29 Y | F | U/A | <-70C | 06-Apr-18 | Roche cobas 602 | ECLIA | 0.04 | Hepatitis C | T. Vaginalis | Not Detected | Anti HSV 1 IgG | Negative | $100.00 | Anti HSV 1 IgG Quantitative | 0.634 | Anti HSV 2 IgG | Negative | Anti HSV 2 IgG Quantitative | 0.114 | N. Gonorrhoeae | Not Detected | Treponema pallidum ab | Negative | C. Trachomatis | Not Detected | HIV 1| 2 Ag|Ab Combo | Non Reactive | |||||||||||
| KH18-37365 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 16 Y | F | White | <-70C | 23-Aug-18 | Abbott Architect | Negative | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-37366 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 17 Y | F | Black | <-70C | 23-Aug-18 | Abbott Architect | Negative | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-37370 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 17 Y | F | Black | <-70C | 23-Aug-18 | Abbott Architect | Negative | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-36546 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 16 Y | F | Black | <-70C | 16-Aug-18 | Abbott Architect | Negative | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-36548 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 16 Y | F | Black | <-70C | 17-Aug-18 | Abbott Architect | Negative | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-36553 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 16 Y | F | White | <-70C | 22-Aug-18 | Abbott Architect | Negative | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-36554 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 15 Y | F | Black | <-70C | 17-Aug-18 | Abbott Architect | Negative | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-45193 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 65 Y | F | Black | <-70C | 15-Oct-18 | Abbott Architect | 14.21 + | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-45194 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.50 | 1.00 | $65.00 | 46 Y | F | American Indian | <-70C | 08-Oct-18 | Abbott Architect | 7.25 + | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-53116 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 54 Y | F | White | <-70C | 31-Oct-18 | Abbott Architect | 1.35 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54861 | Hepatitis C (HCV) | USA | Serum | 1.75 | 1.00 | $65.00 | 58 Y | M | Black | <-70C | 02-Nov-18 | Abbott Architect | 15.44 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54862 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 23 Y | F | White | <-70C | 10-Nov-18 | Abbott Architect | 12.94 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54863 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 50 Y | F | White | <-70C | 10-Nov-18 | Abbott Architect | 13.77 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54864 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 56 Y | M | White | <-70C | 11-Nov-18 | Abbott Architect | 8.93 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54865 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 56 Y | F | Black | <-70C | 13-Nov-18 | Abbott Architect | 11.38 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54866 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 55 Y | F | Black | <-70C | 16-Nov-18 | Abbott Architect | 13.97 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54867 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 26 Y | M | White | <-70C | 13-Nov-18 | Abbott Architect | 13.53 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54868 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 32 Y | M | U/A | <-70C | 15-Nov-18 | Abbott Architect | 14.62 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54869 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 33 Y | M | White | <-70C | 10-Nov-18 | Abbott Architect | 11.29 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54870 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 37 Y | F | U/A | <-70C | 05-Nov-18 | Abbott Architect | 4.64 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54871 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 51 Y | M | White | <-70C | 04-Nov-18 | Abbott Architect | 6.57 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54872 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 64 Y | M | White | <-70C | 08-Nov-18 | Abbott Architect | 1.04 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54874 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 59 Y | M | Black | <-70C | 15-Nov-18 | Abbott Architect | 5.83 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54875 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 29 Y | M | White | <-70C | 16-Nov-18 | Abbott Architect | 14.08 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-54876 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 27 Y | F | White | <-70C | 06-Nov-18 | Abbott Architect | 15.09 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-53441 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 61 Y | M | White | <-70C | 14-Nov-18 | Abbott Architect | 10.89 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-53442 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 40 Y | F | White | <-70C | 12-Nov-18 | Abbott Architect | 5.03 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH18-53443 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 57 Y | M | White | <-70C | 09-Nov-18 | Abbott Architect | 14.49 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-01068 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 56 Y | M | Black | <-70C | 25-Nov-18 | Abbott Architect | 11.87 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-01115 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 59 Y | F | Black | <-70C | 29-Nov-18 | Abbott Architect | 1.18 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-01116 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 27 Y | M | White | <-70C | 29-Nov-18 | Abbott Architect | 2.13 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-01117 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 32 Y | M | U/A | <-70C | 27-Nov-18 | Abbott Architect | 11.59 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-01118 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 31 Y | M | White | <-70C | 27-Nov-18 | Abbott Architect | 14.03 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-01119 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 68 Y | F | White | <-70C | 30-Nov-18 | Abbott Architect | 11.72 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-02601 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 37 Y | M | White | <-70C | 11-Dec-18 | Abbott Architect | 16.67 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-02602 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 59 Y | F | White | <-70C | 12-Dec-18 | Abbott Architect | 13.43 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-02605 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 69 Y | M | White | <-70C | 13-Dec-18 | Abbott Architect | 11.12 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-02606 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 27 Y | F | Black | <-70C | 13-Dec-18 | Abbott Architect | 10.03 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-02608 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 52 Y | F | White | <-70C | 16-Dec-18 | Abbott Architect | 12.94 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-02609 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 31 Y | M | White | <-70C | 17-Dec-18 | Abbott Architect | 15.75 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-04095 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 75 Y | F | White | <-70C | 20-Dec-18 | Abbott Architect | 2.47 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-04096 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 37 Y | F | White | <-70C | 17-Dec-18 | Abbott Architect | 18.29 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03597 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 48 Y | F | Black | <-70C | 31-Dec-18 | Abbott Architect | 2.8 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03598 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 33 Y | F | White | <-70C | 04-Jan-19 | Abbott Architect | 13.49 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03599 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 31 Y | M | White | <-70C | 03-Jan-19 | Abbott Architect | 14.73 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03600 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 27 Y | M | White | <-70C | 08-Dec-18 | Abbott Architect | 13.55 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03601 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 26 Y | M | White | <-70C | 02-Jan-19 | Abbott Architect | 12.25 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03856 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 37 Y | M | U/A | <-70C | 08-Jan-19 | Abbott Architect | 11.94 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03857 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 44 Y | M | White | <-70C | 14-Jan-19 | Abbott Architect | 16.58 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03858 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 26 Y | M | Black | <-70C | 10-Jan-19 | Abbott Architect | 1.68 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03859 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 23 Y | F | U/A | <-70C | 12-Jan-19 | Abbott Architect | 14.84 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03860 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 22 Y | M | Black | <-70C | 15-Jan-19 | Abbott Architect | 14.46 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03861 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 61 Y | F | Black | <-70C | 10-Jan-19 | Abbott Architect | 11.11 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03862 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 66 Y | F | Black | <-70C | 10-Jan-19 | Abbott Architect | 13.15 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03863 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 70 Y | M | Black | <-70C | 10-Jan-19 | Abbott Architect | 8.44 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03864 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 49 Y | M | Black | <-70C | 10-Jan-19 | Abbott Architect | 11.46 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03865 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 35 Y | M | White | <-70C | 12-Jan-19 | Abbott Architect | 14.30 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-03866 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 40 Y | F | U/A | <-70C | 10-Jan-19 | Abbott Architect | 12.65 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KHBR-1584 | Hepatitis C (HCV) | USA | Serum | 2.25 | 1.00 | $75.00 | 27 Y | F | White | <-70C | 31-Oct-17 | Abbott Architect | Positive | HCV | $75.00 | IV Drug Use | Date of Freeze | 01.09.18 | ||||||||||||||||||||||||||
| KHBR-1737 | Hepatitis C (HCV) | USA | Serum | 1.75 | 1.00 | $75.00 | 61 Y | F | White | <-70C | 17-Apr-18 | Roche COBAS | Taqman | 142,170 IU/mL | HCV Viral Load | $75.00 | Date of Freeze | 05.15.18 | B19.2 | ||||||||||||||||||||||||||
| KH19-06085 | Hepatitis C (HCV) | USA | Serum | 1.75 | 1.00 | $65.00 | 66 Y | M | U/A | <-70C | 11-Jan-19 | Abbott Architect | 13.74 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06086 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 34 Y | F | Asian | <-70C | 11-Jan-19 | Abbott Architect | 9.58 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06087 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 52 Y | M | Black | <-70C | 11-Jan-19 | Abbott Architect | 2.31 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06088 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 49 Y | M | Black | <-70C | 10-Jan-19 | Abbott Architect | 1.37 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06089 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 26 Y | F | White | <-70C | 17-Jan-19 | Abbott Architect | 15.39 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06090 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 38 Y | F | Black | <-70C | 17-Jan-19 | Abbott Architect | 2.56 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06091 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 38 Y | M | U/A | <-70C | 21-Jan-19 | Abbott Architect | 12.56 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06092 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 40 Y | M | White | <-70C | 20-Jan-19 | Abbott Architect | 14.51 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06093 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 30 Y | F | White | <-70C | 20-Jan-19 | Abbott Architect | 14.33 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06094 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 56 Y | F | Black | <-70C | 16-Jan-19 | Abbott Architect | 15.42 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06095 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 61 Y | M | Black | <-70C | 16-Jan-19 | Abbott Architect | 9.48 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06096 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 54 Y | M | White | <-70C | 16-Jan-19 | Abbott Architect | 1.22 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06097 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 81 Y | M | Black | <-70C | 15-Jan-19 | Abbott Architect | 10.67 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-06098 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 60 Y | M | White | <-70C | 15-Jan-19 | Abbott Architect | 14.33 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-071107 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 21 Y | F | White | <-70C | 26-Jan-19 | Abbott Architect | 14.61 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-071108 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 30 Y | M | White | <-70C | 25-Jan-19 | Abbott Architect | 13.65 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-071109 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 47 Y | M | American Indian | <-70C | 28-Jan-19 | Abbott Architect | 15.76 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-071110 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 18 Y | F | White | <-70C | 28-Jan-19 | Abbott Architect | 14.62 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-071111 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 58 Y | M | White | <-70C | 25-Jan-19 | Abbott Architect | 10.88 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-071112 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 48 Y | M | Black | <-70C | 24-Jan-19 | Abbott Architect | 14.29 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-071113 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 44 Y | F | Black | <-70C | 24-Jan-19 | Abbott Architect | 1.14 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-071114 | Hepatitis C (HCV) | USA | Serum | 1.00 | 1.00 | $65.00 | 68 Y | M | Black | <-70C | 22-Jan-19 | Abbott Architect | 11.19 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KHBR19-00006 | Hepatitis C (HCV) | USA | Serum | 1.30 | 1.00 | $65.00 | 31 Y | F | White | <-70C | 02-Feb-19 | Viral Load | 1,708,323 IU/mL | HCV RNA | $65.00 | Freeze Date | 2/28/2019 | |||||||||||||||||||||||||||
| KHBR19-00072 | Hepatitis C (HCV) | USA | Serum | 1.50 | 1.00 | $65.00 | 65 Y | M | U/A | <-70C | 05-Feb-19 | Roche COBAS | Taqman | 8,319,879 IU/mL | HCV RNA PCR | $65.00 | Freeze Date | 05.21.19 | |||||||||||||||||||||||||||
| DLS0075812 | Hepatitis C (HCV) | USA | Serum | 1.25 | 1.00 | $65.00 | 28 Y | M | White | <-70C | 21-Jan-19 | Abbott Architect i2000 | 1,182 IU/mL | HCV AB | $65.00 | F11.10, H52.03, H53.001, Z97.3, B18.2, S60.552A | ||||||||||||||||||||||||||||
| KH19-087830 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.25 | 1.00 | $65.00 | 19 Y | F | U/A | <-70C | 25-Jun-19 | Abbott Architect | 16.23 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-087829 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 51 Y | M | American Indian | <-70C | 25-Jun-19 | Abbott Architect | 15.72 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-088450 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 62 Y | F | Black | <-70C | 16-Jul-19 | Abbott Architect I2000 | CMIA | 15.42 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-088451 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.50 | 1.00 | $65.00 | 62 Y | F | Black | <-70C | 15-Jul-19 | Abbott Architect I2000 | CMIA | 0.8 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-088910 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.25 | 1.00 | $65.00 | 48 Y | M | Black | <-70C | 23-Jul-19 | Abbott Architect I2000 | CMIA | 1.52 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-088911 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.25 | 1.00 | $65.00 | 57 Y | F | White | <-70C | 05-Jul-19 | Abbott Architect I2000 | CMIA | 10.15 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-088912 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.25 | 1.00 | $65.00 | 32 Y | F | White | <-70C | 05-Jul-19 | Abbott Architect I2000 | CMIA | 14.07 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-089401 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.75 | 1.00 | $65.00 | 34 Y | F | White | <-70C | 25-Jul-19 | Abbott Architect I2000 | CMIA | 12.08 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-089402 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 59 Y | F | White | <-70C | 25-Jul-19 | Abbott Architect I2000 | CMIA | 10.23 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-091377 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.25 | 1.00 | $65.00 | 61 Y | M | Black | <-70C | 02-Aug-19 | Abbott Architect I2000 | CMIA | 14.97 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-091378 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.25 | 1.00 | $65.00 | 53 Y | F | Black | <-70C | 02-Aug-19 | Abbott Architect I2000 | CMIA | 2.51 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-091379 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.25 | 1.00 | $65.00 | 32 Y | F | White | <-70C | 06-Jul-19 | Abbott Architect I2000 | CMIA | 14.07 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-091376 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.50 | 1.00 | $65.00 | 53 Y | M | White | <-70C | 01-Aug-19 | Abbott Architect I2000 | CMIA | 13.39 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-090079 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.50 | 1.00 | $65.00 | 47 Y | F | Black | <-70C | 12-Aug-19 | Abbott Architect I2000 | CMIA | 15.91 IU/mL | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-090078 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.50 | 1.00 | $65.00 | 54 Y | M | Black | <-70C | 09-Aug-19 | Abbott Architect I2000 | CMIA | 14.07 IU/mL | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-090077 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.50 | 1.00 | $65.00 | 50 Y | M | White | <-70C | 06-Aug-19 | Abbott Architect I2000 | CMIA | 14.39 IU/mL | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-092096 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 55 Y | M | White | <-70C | 14-Aug-19 | Abbott Architect I2000 | CMIA | 5.13 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-092097 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 45 Y | M | White | <-70C | 17-Aug-19 | Abbott Architect I2000 | CMIA | 14.07 | HCV Ab | $65.00 | |||||||||||||||||||||||||||||
| KH19-086492 | Hepatitis C (HCV) | USA | K2 EDTA Plasma | 1.00 | 1.00 | $65.00 | 59 Y | M | White | <-70C | 23-Aug-19 | Abbott Architect I2000 | CMIA | 17.36 | HCV Ab | $65.00 |
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.